Klebsiella pneumoniae — The Encapsulated Opportunist

Table of Contents

  1. Discovery and Microbiology
  2. Virulence Factors
  3. Diseases Caused
  4. Hypervirulent Klebsiella pneumoniae
  5. Antibiotic Resistance — A Global Crisis
  6. Conventional Treatment
  7. Natural Herbs with Activity Against Klebsiella
  8. Capsule Disruption by Natural Compounds
  9. Hospital Infection Prevention
  10. Key Research Papers and References

1. Discovery and Microbiology

Klebsiella pneumoniae was first isolated and described by the German pathologist Carl Friedlander in 1882, who identified it in the lungs of patients who had died from pneumonia. Friedlander initially named the organism Friedlander's bacillus, and for decades it was recognized as a major cause of severe lobar pneumonia. The genus name Klebsiella was later assigned in honor of Edwin Klebs, the pioneering German-Swiss microbiologist whose foundational contributions to bacteriology helped shape the field in the late nineteenth century.

Klebsiella pneumoniae is a Gram-negative, non-motile, facultatively anaerobic rod-shaped bacterium belonging to the family Enterobacteriaceae. The organism typically measures 0.3 to 1.0 micrometers in width and 0.6 to 6.0 micrometers in length. It is encapsulated, oxidase-negative, catalase-positive, and ferments lactose, producing mucoid colonies on MacConkey agar that are easily distinguishable from other enteric bacteria.

One of the most distinctive features of K. pneumoniae is its prominent polysaccharide capsule, which gives colonies their characteristically mucoid, glistening appearance. This capsule is the organism's primary defense against the host immune system, shielding it from phagocytosis by neutrophils and macrophages. More than 80 capsular serotypes (K antigens) have been identified, with types K1 and K2 being particularly associated with invasive disease.

K. pneumoniae is a normal commensal organism of the human gastrointestinal tract, colonizing the intestinal mucosa in approximately 5 to 38 percent of healthy individuals. It is also found in the nasopharynx of about 1 to 6 percent of healthy people. In its commensal state, the organism causes no disease. However, when the host's immune defenses are compromised, or when the bacterium gains access to normally sterile body sites, it can cause a wide range of serious infections.

2. Virulence Factors

The pathogenic success of K. pneumoniae is attributable to a sophisticated arsenal of virulence factors that enable colonization, immune evasion, nutrient acquisition, and tissue invasion. Understanding these factors is essential for developing effective therapies and prevention strategies.

Polysaccharide Capsule (K Antigens)

The thick polysaccharide capsule is the single most important virulence determinant of K. pneumoniae. Composed of repeating units of sugars including mannose, rhamnose, glucose, and glucuronic acid, the capsule forms a hydrated shield around the bacterial cell. This capsule prevents complement-mediated opsonization and inhibits phagocytic uptake by immune cells. The capsule also interferes with the binding of antimicrobial peptides such as defensins and cathelicidins. Clinical isolates with thicker capsules consistently demonstrate higher virulence in animal models. Over 80 distinct K antigen serotypes exist, with K1 and K2 strains showing the greatest association with invasive infections including liver abscess and bacteremia.

Lipopolysaccharide (LPS)

The lipopolysaccharide of K. pneumoniae, also called endotoxin, is an integral component of the outer membrane. The lipid A moiety triggers potent inflammatory responses through activation of Toll-like receptor 4 (TLR4) on innate immune cells. The O-antigen polysaccharide chain provides serum resistance by preventing insertion of the membrane attack complex. Nine O-antigen serotypes (O1 to O9) have been identified, with O1 being the most prevalent among clinical isolates and associated with increased resistance to complement-mediated killing.

Siderophores

K. pneumoniae produces multiple iron-scavenging siderophores to acquire this essential nutrient from the iron-limited host environment. Enterobactin is a catecholate siderophore with the highest known affinity for ferric iron among biological molecules. Aerobactin is a hydroxamate siderophore that, while having lower iron affinity than enterobactin, is more effective in vivo because it is resistant to the host protein lipocalin-2 (also called siderocalin), which specifically sequesters enterobactin. Hypervirulent strains additionally produce yersiniabactin and salmochelin, which further enhance iron acquisition and virulence. The presence of multiple siderophore systems provides redundancy and adaptability across different host niches.

Fimbriae (Pili)

Type 1 fimbriae are mannose-sensitive adhesins expressed by nearly all K. pneumoniae strains. They mediate attachment to uroepithelial cells and are critical for urinary tract colonization and biofilm formation on catheter surfaces. Type 3 fimbriae (encoded by the mrkABCDF gene cluster) bind to extracellular matrix proteins including collagen and fibronectin, facilitating adhesion to respiratory epithelium, renal tubular cells, and abiotic surfaces such as endotracheal tubes and intravenous catheters. Both fimbrial types play essential roles in biofilm development, which contributes to persistent infections and reduced antibiotic susceptibility.

Hypermucoviscosity and the String Test

Hypervirulent strains of K. pneumoniae often exhibit a hypermucoviscous phenotype, producing an exceptionally thick, viscous capsule. This phenotype is detected by the "string test," in which a standard bacteriological loop is used to touch a colony grown on an agar plate. If a viscous string of 5 millimeters or longer stretches from the colony, the test is considered positive. The hypermucoviscosity phenotype is regulated by genes including rmpA (regulator of mucoid phenotype A) and rmpA2, and is strongly associated with invasive disease, particularly pyogenic liver abscess.

3. Diseases Caused

K. pneumoniae is responsible for a broad spectrum of infections, ranging from community-acquired to healthcare-associated diseases. The clinical manifestations depend on the site of infection, the virulence profile of the infecting strain, and the immune status of the host.

Community-Acquired Pneumonia

Classical Klebsiella pneumonia, as originally described by Friedlander, is a severe necrotizing infection that primarily affects individuals with compromised pulmonary defenses, including chronic alcoholics, diabetics, and the elderly. The hallmark of Klebsiella pneumonia is the production of thick, bloody, mucoid sputum classically described as "currant jelly sputum" due to its dark red, gelatinous appearance caused by the mixture of blood, mucus, and the organism's polysaccharide capsule. Chest radiographs typically reveal a dense lobar consolidation, frequently in the upper lobes, with a characteristic bulging of the interlobar fissure caused by the massive inflammatory exudate. Without prompt treatment, mortality rates can exceed 50 percent, even with modern supportive care.

Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia

K. pneumoniae is one of the leading causes of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), particularly in intensive care units. Endotracheal intubation disrupts the normal mucosal barriers and provides a surface for biofilm formation by type 3 fimbriae. Colonization of the oropharynx with K. pneumoniae, often facilitated by prior antibiotic therapy that disrupts the normal flora, precedes aspiration into the lower airways. Hospital-acquired strains frequently carry extended-spectrum beta-lactamase (ESBL) genes or carbapenemase genes, severely limiting treatment options.

Urinary Tract Infections

K. pneumoniae is the second most common cause of Gram-negative urinary tract infections after Escherichia coli. It is particularly prevalent in catheter-associated UTIs, where type 1 and type 3 fimbriae enable adherence to catheter surfaces and formation of antibiotic-resistant biofilms. Complicated UTIs caused by K. pneumoniae can progress to pyelonephritis, perinephric abscess, and urosepsis, especially in patients with urinary obstruction, diabetes, or immunosuppression.

Bloodstream Infections

K. pneumoniae bacteremia can originate from any primary infection site, including the urinary tract, lungs, biliary system, or intra-abdominal infections. Mortality rates for K. pneumoniae bloodstream infections range from 20 to 50 percent, and are significantly higher when caused by multidrug-resistant strains. Bacteremia caused by carbapenem-resistant K. pneumoniae (CRKP) carries mortality rates exceeding 40 to 70 percent in many studies.

Pyogenic Liver Abscess

A distinctive and increasingly recognized syndrome is community-acquired pyogenic liver abscess caused by hypervirulent K. pneumoniae strains, particularly capsular types K1 and K2. This syndrome was first described in Taiwan in the 1980s and has since been reported globally, though it remains most prevalent in East and Southeast Asia. The infection can disseminate hematogenously to cause metastatic complications including endophthalmitis (which may result in permanent vision loss), meningitis, brain abscess, lung abscess, and necrotizing fasciitis.

Wound Infections and Surgical Site Infections

K. pneumoniae is a significant cause of wound infections and surgical site infections, particularly in healthcare settings. Contamination of surgical wounds with multidrug-resistant strains can lead to deep tissue infections, abscess formation, and bacteremia. Patients with diabetes mellitus are at particular risk due to impaired neutrophil function and compromised wound healing.

Neonatal Sepsis and Meningitis

K. pneumoniae is a leading cause of neonatal sepsis in low- and middle-income countries, where it is responsible for up to 25 percent of neonatal bloodstream infections in some regions. Premature and low-birth-weight infants in neonatal intensive care units are particularly vulnerable. Neonatal Klebsiella meningitis carries high mortality rates and significant risk of long-term neurological sequelae. Outbreaks of ESBL-producing K. pneumoniae in neonatal units have been reported worldwide and are particularly difficult to control.

4. Hypervirulent Klebsiella pneumoniae

Hypervirulent Klebsiella pneumoniae (hvKp) represents a distinct pathotype that causes severe, invasive, community-acquired infections in otherwise healthy individuals. This stands in stark contrast to classical K. pneumoniae (cKp), which primarily causes opportunistic infections in debilitated or hospitalized patients.

Hypervirulent strains are predominantly of capsular serotypes K1 and K2, although other serotypes including K5, K20, K54, and K57 have also been associated with the hypervirulent phenotype. The defining feature of hvKp is its capacity to cause community-acquired pyogenic liver abscess syndrome, first systematically described in Taiwan in the 1980s. Affected patients, many of whom are diabetic but otherwise immunocompetent, develop large hepatic abscesses that can seed metastatic infections to distant sites.

The genetic basis of hypervirulence is primarily encoded on a large virulence plasmid (typically 200 to 250 kilobases) that carries several critical virulence determinants. The rmpA and rmpA2 genes upregulate capsule production, resulting in the hypermucoviscous phenotype. The aerobactin biosynthesis cluster (iucABCD) and its receptor (iutA) provide enhanced iron acquisition capabilities that are essential for systemic infection. The salmochelin siderophore system (iroBCDN) evades the host innate immune defense lipocalin-2. Additional virulence factors encoded on this plasmid include the colibactin genotoxin and metabolic fitness genes.

The epidemiology of hvKp infections shows a striking geographic distribution. While the majority of cases have been reported from Taiwan, South Korea, China, and other parts of East and Southeast Asia, hypervirulent K. pneumoniae infections are increasingly being recognized in Europe, North America, Africa, and the Middle East. Diabetes mellitus is the most common underlying condition, present in 30 to 75 percent of affected patients across different studies.

Of particular concern is the recent convergence of hypervirulence and multidrug resistance, with reports of hvKp strains that have acquired ESBL genes or carbapenemase genes. These convergent strains combine the capacity to cause severe invasive infections in healthy individuals with resistance to last-line antibiotics, representing a potentially catastrophic public health threat.

5. Antibiotic Resistance — A Global Crisis

K. pneumoniae has emerged as one of the most problematic drug-resistant pathogens worldwide. The World Health Organization has designated carbapenem-resistant K. pneumoniae as a "critical priority" pathogen on its global priority list of antibiotic-resistant bacteria, the highest category of urgency for research and development of new treatments.

Extended-Spectrum Beta-Lactamase (ESBL) Production

ESBL-producing K. pneumoniae first emerged in the 1980s and has since become endemic in healthcare settings worldwide. ESBLs are plasmid-mediated enzymes, primarily of the CTX-M, SHV, and TEM families, that hydrolyze penicillins, cephalosporins (including third- and fourth-generation agents such as ceftriaxone, cefotaxime, and cefepime), and aztreonam. ESBL genes are carried on mobile genetic elements that also harbor resistance determinants for aminoglycosides, fluoroquinolones, trimethoprim-sulfamethoxazole, and other antibiotic classes, resulting in a multidrug-resistant phenotype. In many hospitals in southern Europe, Asia, and Latin America, over 50 percent of K. pneumoniae bloodstream isolates produce ESBLs.

Carbapenem-Resistant K. pneumoniae (CRKP)

The emergence of carbapenem resistance in K. pneumoniae is among the most alarming developments in antimicrobial resistance. Carbapenems (imipenem, meropenem, ertapenem, doripenem) had been the last reliable beta-lactam antibiotics for treating ESBL-producing infections. Resistance is primarily mediated by carbapenemase enzymes, particularly Klebsiella pneumoniae carbapenemase (KPC), which was first identified in a clinical isolate from North Carolina in 1996 and has since spread globally. KPC enzymes hydrolyze all beta-lactam antibiotics including carbapenems, cephalosporins, and penicillins.

NDM-1 and Other Metallo-Beta-Lactamases

New Delhi metallo-beta-lactamase 1 (NDM-1), first reported in 2008 in a patient who had received medical care in India, is a zinc-dependent carbapenemase that confers resistance to all beta-lactam antibiotics except aztreonam. NDM-producing K. pneumoniae strains are endemic in the Indian subcontinent and have spread to every inhabited continent. Other metallo-beta-lactamases found in K. pneumoniae include VIM and IMP types. Unlike KPC enzymes, metallo-beta-lactamases are not inhibited by avibactam, limiting treatment options even with newer beta-lactam/beta-lactamase inhibitor combinations.

Colistin Resistance

Colistin (polymyxin E) had been reserved as a last-resort antibiotic for treating carbapenem-resistant infections. The discovery in 2015 of mcr-1 (mobilized colistin resistance), a plasmid-mediated gene conferring colistin resistance, was a watershed moment in antimicrobial resistance. The mcr gene family (now mcr-1 through mcr-10) encodes phosphoethanolamine transferases that modify the lipid A component of lipopolysaccharide, reducing colistin binding. Multiple reports have documented K. pneumoniae strains carrying both carbapenemase genes and mcr genes, creating organisms resistant to virtually all available antibiotics.

Pan-Drug Resistance

The emergence of pan-drug-resistant (PDR) K. pneumoniae — strains resistant to all tested antimicrobial agents including carbapenems, colistin, tigecycline, aminoglycosides, and fosfomycin — has been documented in several countries including Greece, Italy, China, and Brazil. These untreatable infections carry mortality rates approaching 60 to 70 percent. The accumulation of resistance mechanisms through horizontal gene transfer, combined with selective pressure from antibiotic use, continues to drive the evolution of increasingly resistant strains.

6. Conventional Treatment

Treatment of K. pneumoniae infections depends on the susceptibility profile of the infecting strain, the site and severity of infection, and patient-specific factors. The escalating prevalence of resistance has made empiric treatment decisions increasingly complex.

Treatment of ESBL-Producing Infections

Carbapenems remain the standard of care for serious infections caused by ESBL-producing K. pneumoniae. Meropenem and imipenem-cilastatin are the most commonly used agents, administered intravenously. Ertapenem may be appropriate for less severe infections or step-down therapy. For uncomplicated urinary tract infections caused by ESBL producers, alternative agents such as nitrofurantoin, fosfomycin, or trimethoprim-sulfamethoxazole may be effective if susceptibility is confirmed.

Treatment of Carbapenem-Resistant Infections

Treatment options for CRKP infections are severely limited. Historically, colistin-based combination therapy and tigecycline were the primary options, but both have significant limitations. Colistin causes nephrotoxicity in 20 to 60 percent of patients and has suboptimal pharmacokinetics in the lungs. Tigecycline achieves low serum concentrations and has been associated with increased mortality in bloodstream infections.

Newer agents have expanded the treatment armamentarium. Ceftazidime-avibactam, approved in 2015, is effective against KPC-producing strains and has demonstrated improved outcomes compared to colistin-based regimens in observational studies. Meropenem-vaborbactam and imipenem-cilastatin-relebactam are additional carbapenem/beta-lactamase inhibitor combinations active against KPC producers. Cefiderocol, a siderophore cephalosporin, has activity against metallo-beta-lactamase-producing strains including NDM producers.

Combination Therapy

For severe CRKP infections, combination antibiotic therapy is generally recommended. Common regimens include a carbapenem (at high dose, extended infusion) combined with colistin, or ceftazidime-avibactam combined with aztreonam (the latter combination providing coverage against metallo-beta-lactamase producers). The rationale for combination therapy includes achieving synergistic bactericidal activity, preventing emergence of resistance during therapy, and providing broader coverage when susceptibility results are pending.

Pan-Resistant Infections

For the fortunately still rare pan-drug-resistant infections, no reliable treatment exists. Experimental approaches include bacteriophage therapy, novel antimicrobial peptides, and compassionate use of investigational agents. Double carbapenem therapy (ertapenem combined with meropenem or doripenem) has shown some efficacy in case reports, based on the concept that ertapenem acts as a "suicide substrate" for KPC, allowing the second carbapenem to reach bactericidal concentrations.

7. Natural Herbs with Activity Against Klebsiella

While natural compounds cannot replace antibiotics for treating active K. pneumoniae infections, research has identified several plant-derived substances with significant in vitro activity against Klebsiella species. These compounds may serve as complementary agents, sources of novel drug leads, or adjuncts to conventional antibiotic therapy.

Oregano (Origanum vulgare)

Oregano essential oil, particularly its primary constituent carvacrol, has demonstrated potent antibacterial activity against K. pneumoniae. Carvacrol disrupts bacterial membrane integrity by integrating into the lipid bilayer, causing increased permeability and leakage of cellular contents. Studies have reported minimum inhibitory concentrations (MICs) of oregano oil against K. pneumoniae ranging from 0.03 to 0.5 percent (volume/volume), with carvacrol showing MIC values of 128 to 256 micrograms per milliliter against clinical isolates. Notably, carvacrol has shown activity against both ESBL-producing and carbapenem-resistant strains, suggesting that its membrane-targeting mechanism bypasses conventional resistance mechanisms.

Garlic (Allium sativum)

Garlic and its primary bioactive compound allicin have well-documented antibacterial properties against a broad range of Gram-negative bacteria including K. pneumoniae. Allicin inhibits thiol-dependent enzymes through interaction with sulfhydryl groups, disrupting essential metabolic processes. Aqueous garlic extracts have demonstrated MICs of 4 to 32 milligrams per milliliter against clinical K. pneumoniae isolates. Synergistic interactions between garlic extract and aminoglycosides against multidrug-resistant K. pneumoniae have been documented, with fractional inhibitory concentration (FIC) indices below 0.5, indicating true synergy. Ajoene, a secondary organosulfur compound derived from allicin, has additionally shown anti-biofilm activity against K. pneumoniae at sub-inhibitory concentrations.

Andrographis (Andrographis paniculata)

Andrographis has attracted considerable research interest for its synergistic interactions with conventional antibiotics against resistant Gram-negative bacteria. Andrographolide, the primary diterpene lactone, has demonstrated the ability to potentiate the activity of carbapenems against CRKP strains. In vitro studies have shown that andrographolide at sub-inhibitory concentrations (16 to 64 micrograms per milliliter) reduced the MIC of meropenem by 4- to 8-fold against KPC-producing K. pneumoniae. The mechanism involves inhibition of efflux pump activity and disruption of capsule biosynthesis, both of which contribute to enhanced antibiotic penetration and efficacy.

Thyme (Thymus vulgaris)

Thyme essential oil contains thymol and carvacrol as its major phenolic components. Thymol disrupts the outer membrane of Gram-negative bacteria by chelating divalent cations that stabilize lipopolysaccharide. Against K. pneumoniae, thyme oil has shown MIC values of 0.06 to 1.0 percent (volume/volume), with thymol demonstrating MICs of 64 to 512 micrograms per milliliter. Time-kill studies have demonstrated bactericidal activity of thyme oil against ESBL-producing K. pneumoniae within 2 to 4 hours of exposure at twice the MIC concentration.

Eucalyptus (Eucalyptus globulus)

Eucalyptus oil and its primary constituent 1,8-cineole (eucalyptol) have shown moderate antibacterial activity against K. pneumoniae, with MIC values for eucalyptus oil ranging from 0.5 to 4.0 percent (volume/volume). While eucalyptol alone has relatively weak direct antibacterial activity, it has demonstrated significant ability to enhance the permeability of the K. pneumoniae outer membrane, facilitating the entry of conventional antibiotics. Studies have reported synergistic interactions between eucalyptus oil and chloramphenicol, with 2- to 4-fold reductions in antibiotic MICs in the presence of sub-inhibitory concentrations of eucalyptol.

Berberine-Containing Herbs

Berberine, an isoquinoline alkaloid found in goldenseal, barberry, and Oregon grape, has demonstrated activity against K. pneumoniae with MIC values of 32 to 256 micrograms per milliliter. Berberine intercalates into bacterial DNA, inhibits the enzyme FtsZ required for cell division, and disrupts membrane function. Against ESBL-producing K. pneumoniae, berberine has shown synergistic activity when combined with cefazolin, reducing the antibiotic MIC by 8- to 16-fold. Additionally, berberine inhibits biofilm formation by K. pneumoniae at sub-MIC concentrations by suppressing expression of type 3 fimbrial genes.

8. Capsule Disruption by Natural Compounds

The polysaccharide capsule of K. pneumoniae represents a critical barrier to effective immune clearance and antibiotic penetration. The capsule shields the bacterium from complement-mediated killing, phagocytosis, and the activity of cationic antimicrobial peptides. In biofilm-associated infections, the capsule contributes to the extracellular matrix that further reduces antibiotic diffusion. Disrupting capsule production or integrity therefore represents a promising therapeutic strategy, and several natural compounds have shown capacity to interfere with this essential virulence factor.

Andrographolide and Capsule Formation

Andrographolide, the bioactive diterpene lactone from Andrographis paniculata, has been shown to inhibit capsule biosynthesis in K. pneumoniae through downregulation of the cps (capsular polysaccharide synthesis) gene cluster. At sub-inhibitory concentrations of 16 to 32 micrograms per milliliter, andrographolide reduced capsule production by 40 to 60 percent as measured by uronic acid assays. Transmission electron microscopy confirmed visible thinning of the capsule layer in treated bacteria. This capsule reduction significantly enhanced phagocytic killing by human neutrophils and increased susceptibility to complement-mediated lysis. The combination of andrographolide with meropenem showed enhanced bactericidal activity against CRKP strains, with the capsule-disrupting effect allowing greater antibiotic penetration to the bacterial cell surface.

Garlic Allicin and Capsule Integrity

Allicin from Allium sativum has demonstrated effects on the capsule of K. pneumoniae through a different mechanism. Rather than inhibiting capsule biosynthesis, allicin appears to destabilize existing capsule structure through oxidative modification of capsular polysaccharides. At concentrations of 32 to 64 micrograms per milliliter, allicin reduced the viscosity of capsular material and diminished the hypermucoviscous phenotype, as demonstrated by shortened string lengths in the string test. This effect was associated with increased susceptibility to serum killing, suggesting that allicin-mediated capsule disruption restores complement access to the bacterial surface.

Future Research Directions

The concept of "anti-virulence" therapy — targeting bacterial virulence factors rather than bacterial viability — is gaining traction as a strategy to combat multidrug-resistant organisms. Capsule-targeting compounds offer the theoretical advantage of exerting lower selective pressure for resistance compared to conventional bactericidal antibiotics, since they do not directly kill the bacteria but rather render them vulnerable to immune clearance. Combination approaches using capsule-disrupting natural compounds alongside conventional antibiotics or immunotherapy represent a promising area for future clinical investigation. However, the transition from in vitro and animal model data to clinical application requires rigorous pharmacokinetic studies, bioavailability optimization, and controlled clinical trials to establish safety and efficacy in human infections.

9. Hospital Infection Prevention

Preventing the transmission of K. pneumoniae, particularly multidrug-resistant strains, in healthcare settings requires a comprehensive, multimodal infection prevention strategy. The consequences of failure are severe: nosocomial outbreaks of CRKP have caused mortality rates exceeding 50 percent in affected patients.

Hand Hygiene

Hand hygiene is the single most effective measure for preventing healthcare-associated transmission of K. pneumoniae. Alcohol-based hand rubs with at least 60 percent ethanol or isopropanol are effective against K. pneumoniae, although the organism's capsule can confer modest protection against alcohol killing at short exposure times. Healthcare workers must perform hand hygiene before and after every patient contact, before aseptic procedures, after contact with body fluids, and after touching the patient's environment. Compliance monitoring programs with real-time feedback have been shown to reduce CRKP transmission rates by 40 to 70 percent.

Contact Precautions

Patients colonized or infected with multidrug-resistant K. pneumoniae should be placed on contact precautions, including placement in a single room (or cohorting with similarly colonized patients), use of gloves and gowns for all patient contact, and dedicated patient-care equipment. Active surveillance cultures (rectal swabs for carbapenemase-producing Enterobacterales) enable early identification of colonized patients and prompt implementation of contact precautions before transmission can occur.

Antimicrobial Stewardship

Antimicrobial stewardship programs are essential for reducing the selective pressure that drives emergence and spread of resistant K. pneumoniae. Key stewardship interventions include restriction of broad-spectrum antibiotics (particularly carbapenems and fluoroquinolones), prospective audit and feedback on antibiotic prescribing, implementation of antibiotic cycling or mixing strategies, and de-escalation of empiric therapy based on culture results. Studies have demonstrated that effective stewardship programs can reduce the incidence of ESBL-producing and carbapenem-resistant K. pneumoniae by 20 to 50 percent.

Environmental Decontamination

K. pneumoniae can survive on hospital surfaces for days to months, with its polysaccharide capsule conferring desiccation resistance. Enhanced environmental cleaning with sporicidal agents, hydrogen peroxide vapor decontamination of rooms after discharge of colonized patients, and use of antimicrobial copper surfaces have all been shown to reduce environmental contamination. Particular attention should be paid to frequently touched surfaces including bed rails, call buttons, bedside tables, door handles, and electronic devices.

Screening and Surveillance

Active surveillance for CRKP colonization through rectal screening of high-risk patients (ICU admissions, transfers from other facilities, patients with recent hospitalization in endemic regions) is recommended by multiple infectious disease guidelines. Rapid molecular testing using polymerase chain reaction (PCR) for carbapenemase genes allows same-day identification of carriers, enabling immediate implementation of infection control measures. Whole-genome sequencing is increasingly used for outbreak investigation, providing high-resolution tracking of transmission chains and identification of environmental reservoirs.

10. Key Research Papers and References

  1. Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clinical Microbiology Reviews. 1998;11(4):589-603. DOI: 10.1128/CMR.11.4.589
  2. Paczosa MK, Mecsas J. Klebsiella pneumoniae: going on the offense with a strong defense. Microbiology and Molecular Biology Reviews. 2016;80(3):629-661. DOI: 10.1128/MMBR.00078-15
  3. Siu LK, Yeh KM, Lin JC, Fung CP, Chang FY. Klebsiella pneumoniae liver abscess: a new invasive syndrome. The Lancet Infectious Diseases. 2012;12(11):881-887. DOI: 10.1016/S1473-3099(12)70205-0
  4. Russo TA, Marr CM. Hypervirulent Klebsiella pneumoniae. Clinical Microbiology Reviews. 2019;32(3):e00001-19. DOI: 10.1128/CMR.00001-19
  5. Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. The Lancet Infectious Diseases. 2013;13(9):785-796. DOI: 10.1016/S1473-3099(13)70190-7
  6. Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. The Lancet Infectious Diseases. 2016;16(2):161-168. DOI: 10.1016/S1473-3099(15)00474-8
  7. Wyres KL, Lam MMC, Holt KE. Population genomics of Klebsiella pneumoniae. Nature Reviews Microbiology. 2020;18(6):344-359. DOI: 10.1038/s41579-019-0315-1
  8. Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrobial Agents and Chemotherapy. 2017;61(8):e00883-17. DOI: 10.1128/AAC.00883-17
  9. Nostro A, Papalia T. Antimicrobial activity of carvacrol: current progress and future prospectives. Recent Patents on Anti-Infective Drug Discovery. 2012;7(1):28-35. DOI: 10.2174/157489112799829684
  10. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. The Lancet Infectious Diseases. 2018;18(3):318-327. DOI: 10.1016/S1473-3099(17)30753-3
  11. Harada S, Doi Y. Hypervirulent Klebsiella pneumoniae: a call for consensus definition and international collaboration. Journal of Clinical Microbiology. 2018;56(9):e00959-18. DOI: 10.1128/JCM.00959-18
  12. Martin RM, Bachman MA. Colonization, infection, and the accessory genome of Klebsiella pneumoniae. Frontiers in Cellular and Infection Microbiology. 2018;8:4. DOI: 10.3389/fcimb.2018.00004

Back to Table of Contents